- Home
- GECC vs MIST Comparison
GECC vs MIST Comparison
Compare GECC & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GECC
- MIST
- Stock Information
- Founded
- GECC 2016
- MIST 2003
- Country
- GECC United States
- MIST Canada
- Employees
- GECC N/A
- MIST N/A
- Industry
- GECC Finance: Consumer Services
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- GECC Finance
- MIST Health Care
- Exchange
- GECC Nasdaq
- MIST Nasdaq
- Market Cap
- GECC 121.9M
- MIST 100.3M
- IPO Year
- GECC N/A
- MIST N/A
- Fundamental
- Price
- GECC $10.87
- MIST $2.14
- Analyst Decision
- GECC
- MIST Strong Buy
- Analyst Count
- GECC 0
- MIST 3
- Target Price
- GECC N/A
- MIST $13.00
- AVG Volume (30 Days)
- GECC 29.5K
- MIST 641.5K
- Earning Date
- GECC 02-27-2025
- MIST 11-12-2024
- Dividend Yield
- GECC 13.42%
- MIST N/A
- EPS Growth
- GECC N/A
- MIST N/A
- EPS
- GECC 0.65
- MIST N/A
- Revenue
- GECC $39,468,000.00
- MIST N/A
- Revenue This Year
- GECC $17.68
- MIST N/A
- Revenue Next Year
- GECC $4.96
- MIST N/A
- P/E Ratio
- GECC $16.61
- MIST N/A
- Revenue Growth
- GECC 16.86
- MIST N/A
- 52 Week Low
- GECC $9.55
- MIST $1.12
- 52 Week High
- GECC $11.31
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- GECC 60.08
- MIST 58.87
- Support Level
- GECC $10.02
- MIST $1.92
- Resistance Level
- GECC $10.80
- MIST $2.07
- Average True Range (ATR)
- GECC 0.34
- MIST 0.20
- MACD
- GECC 0.03
- MIST -0.02
- Stochastic Oscillator
- GECC 79.63
- MIST 28.24
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. The company seeks to generate current income and capital appreciation through debt and equity investments, including investments in specialty finance businesses. It invests in senior secured and senior unsecured debt instruments, as well as in junior loans and mezzanine debt of middle-market companies and small businesses. The company generates revenue from interest on the debt investments that it holds.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).